netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
netscientific
netscientific
  • ABOUT US
  • TEAM
    • CAREERS
  • PORTFOLIO
  • INVESTORS
    • RNS & RNS REACH
    • FINANCIAL RESULTS
    • CORPORATE GOVERNANCE
  • NEWS
  • CONTACT US

NetScientific invests in Breakout Labs’ portfolio

Dec 8, 2014
-
News, RNS Announcements
RNS Number : 0499Z
NetScientific PLC
08 December 2014

 

NetScientific plc

(‘NetScientific’ or ‘the Group’)

 

NetScientific invests in Breakout Labs’ portfolio company EpiBone

 

8 December 2014: NetScientific (AIM:NSCI), the global biomedical and healthcare technology group, today announced it has made an investment in EpiBone, a revolutionary bone reconstruction company that allows patients to “grow their own bone”. It is the Group’s fourth investment in a Breakout Labs portfolio company since announcing its partnership with Peter Thiel’s revolving philanthropic fund in March 2014.

 

EpiBone’s pioneering technology uses a scan of the patient’s bone defect and the patient’s own stem cells to construct and cultivate a bone graft with the precise anatomical fit to the defect being treated. EpiBone will offer surgeons simplified procedures and patients improved bone formation and regeneration, with shorter recovery times, without the complications of synthetic implants. 

 

Based on 15 years of NIH-funded bone tissue engineering research, EpiBone’s technology was developed by Columbia Professor Gordana Vunjak-Novakovic. The company is led by CEO, Nina Tandon, a former post-doctoral fellow in the Vunjak-Novakoic laboratory and Senior TED Fellow.

 

Farad Azima, CEO, NetScientific, commented: “EpiBone is another excellent example of the revolutionary new technologies in which Breakout Labs is identifying and investing. We look forward to continuing to work with Breakout Lab’s exciting new companies, supporting a new wave of scientific innovation which could transform many areas of healthcare.”

 

Nina Tandon, CEO of EpiBone added: “We are very excited about the support we’ve received from NetScientific at this key juncture in our development program. We plan to utilize the funds to perform key experiments that will pave the way towards clinical trials, and eventually towards the clinic, where we hope our technology will be able to truly transform patient lives.”

 

-Ends-

 

About NetScientific

NetScientific is a global biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net 

 

About Breakout Labs

Breakout Labs, a program of the Thiel Foundation, is reshaping the way early-stage science and technology companies are funded. Breakout Labs supports 19 companies in areas ranging from food science and biomedicine to clean energy. Breakout Labs provides up to $350,000 for companies to achieve specific milestones that are critical to their development. The program provides support in the form of key introductions to potential follow-on funders, refinement of business plans and presentations, an annual demo day with potential investors, and resources that facilitate the process of building their companies. Successful companies will return a capped royalty stream and a small percentage of equity to Breakout Labs and, thereby, contribute to the next generation of scientific innovation. For more information, www.BreakoutLabs.org

 

About EpiBone

EpiBone is a Columbia University spin-out focused on producing fully functional, patient specific, living bone and osteochondral tissues for anatomically challenging defects that severely debilitate the patient and limit quality of life. These defects, whether rendered by trauma, congenital abnormalities, or cancer, require precise, functional, patient specific substitute tissues. EpiBone employs revolutionary, proprietary technology, protected by a suite of patent applications and substantial technical know-how of a world-class scientific hailing from Columbia and MIT.  For more information, please visit http://epibone.com/ 

 

Contact Details

NetScientific plc

Farad Azima

Peter Thoms

 

Tel: +44 (0) 20 3290 8877

Liberum (NOMAD and Broker)

Chris Bowman / Christopher Britton /
Thomas Bective

 

Tel: +44 (0) 20 3100 2000

Instinctif Partners

Melanie Toyne-Sewell / Tim Watson

Tel: +44 (0) 20 7457 2020

Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange

END

MSCBIBDDBXGBGSU

Share on FacebookShare on TwitterShare on Linkedin
← PREVIOUS POST
NetScientific enters into alliance with Healthbox
NEXT POST →
Holding(s) in Company

 

NetScientific plc

Level 39,
One Canada Square,
London, E14 5AB

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS & RNS Reach
  • Financial Results
  • Financial Calendar
  • Corporate Governance
  • News
  • Historic Material
copyright
Terms of Use
NetScientific invests in Breakout Labs' portfolio - NetScientific
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.